Home  /  Resource Library  /  Bridging practices prior to brexucabtagene autoleucel for mantle cell lymphoma in the United Kingdom: An analysis of modality, response, toxicity and survival

Bridging practices prior to brexucabtagene autoleucel for mantle cell lymphoma in the United Kingdom: An analysis of modality, response, toxicity and survival

Study examined bridging therapy before CAR-T Brexucabtagene Autoleucel for treatment of relapsed MCL.